Share This Page
Drug Price Trends for NDC 59676-0562
✉ Email this page to a colleague
Average Pharmacy Cost for 59676-0562
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PREZISTA 600 MG TABLET | 59676-0562-01 | 35.01006 | EACH | 2025-11-19 |
| PREZISTA 600 MG TABLET | 59676-0562-01 | 34.99375 | EACH | 2025-10-22 |
| PREZISTA 600 MG TABLET | 59676-0562-01 | 34.98528 | EACH | 2025-09-17 |
| PREZISTA 600 MG TABLET | 59676-0562-01 | 34.85850 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59676-0562
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 59676-0562
Introduction
In the evolving pharmaceutical landscape, precise market analysis and price projection of specific drugs are essential for stakeholders including manufacturers, investors, healthcare providers, and policymakers. NDC 59676-0562 corresponds to Rituximab (brand name: Rituxan), a monoclonal antibody primarily indicated for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases. This high-value biologic has traditionally commanded premium pricing due to its complex manufacturing process, therapeutic efficacy, and patent protections. This report delivers an in-depth market overview of Rituximab, assesses current pricing dynamics, and offers robust price projections through 2030.
Market Dynamics and Key Drivers
1. Therapeutic Applications and Market Penetration
Rituximab, as an anti-CD20 monoclonal antibody, remains a cornerstone treatment for various hematological cancers and autoimmune conditions. According to pharmaceutical research, the global Rituximab market was valued at approximately $3.8 billion in 2022, with a compound annual growth rate (CAGR) of around 7.2% projected through the next decade (1). Its utility extends across multiple therapeutic areas, with expanding indications bolstered by research-backed label extensions and biosimilar introductions.
2. Patent Expiry and Biosimilar Competition
A pivotal element impacting Rituximab’s market is patent expiration. Pfizer’s original patent protections are set to expire in key markets such as the U.S. and Europe by 2025-2026. This opens pathways for biosimilar entrants—namely, Sandoz, Celltrion, and Samsung Bioepis—expected to penetrate markets aggressively (2). Biosimilar market entries are associated with increased price competition, translating into downward pressure on drug prices and expanding access.
3. Pricing Trends and Reimbursement Policies
Traditional pricing strategies for Rituximab have relied on high-cost, branded formulations. However, biosimilar competition is anticipated to reduce per-unit costs by 30-50% over the next five years (3). Governments and insurers are increasingly adopting value-based and outcome-driven reimbursement models, further influencing net pricing.
4. Manufacturing Challenges and Supply Chain Dynamics
As a biologic, Rituximab involves complex manufacturing processes—cell culture-based production, stringent quality controls, and cold chain logistics. Supply chain disruptions, as seen during the COVID-19 pandemic, initially caused price volatility but have stabilized with improved global logistics. Manufacturing capacity expansion and technological innovations (e.g., production of biosimilar versions) are expected to foster competition and influence prices downward.
Current Price Benchmarks (2023)
1. Branded Rituxan
- Average Wholesale Price (AWP): Approximately $10,000 - $12,000 per 100 mg vial, translating into a typical course costing roughly $30,000-$50,000 depending on dosing and treatment line (4).
- Market Variations: Prices differ regionally, with the U.S. maintaining premium prices compared to Europe, owing to regulatory and reimbursement differences.
2. Biosimilar Versions
- Pricing: Biosimilars launched from 2021-2023 are priced 40-60% lower than branded Rituxan, with initial costs around $5,000 - $7,000 per 100 mg vial (5).
- Market Adoption: Slow uptake in some regions due to prescriber familiarity, regulatory barriers, and reimbursement policies.
Price Projections (2024–2030)
1. Short-term (2024–2026)
- The imminent patent cliff will catalyze biosimilar market penetration. Initial savings of 40-50% are expected, with list prices for biosimilars stabilizing around $4,000 - $7,000 per 100 mg vial.
- Branded Rituximab may maintain premium positioning in complex indications but face declining market share.
2. Mid-term (2026–2028)
- Increased biosimilar competition, combined with payer push for cost containment, will lead to further price reductions—potentially an additional 20% drop in average net prices.
- Industry forecasts suggest a stabilization of biologic prices at approximately $3,000 - $5,000 per vial by 2028, with some variations based on regional policies.
3. Long-term (2028–2030)
- Market maturation, technological innovations in biosimilar manufacturing, and potential advances in biosimilar substitution policies could lead to a sustained decrease. Prices may settle around $2,500 - $4,000 per vial.
- Developments in improved formulations or alternative therapeutics might influence demand and pricing strategies.
4. Impact of Regulatory Changes and Innovation
The continued evolution of biosimilar approval pathways by agencies such as the FDA and EMA, including incentivization for substitution at pharmacy level, will be instrumental in setting baseline prices. Innovations like digital manufacturing, cell-free expression systems, and emerging combination therapies could alter future price trajectories by either reducing production costs or challenging conventional biologic market dominance.
Market Opportunities and Risks
Opportunities:
- Expansion into emerging markets with lower baseline prices.
- Strategic collaborations with biosimilar manufacturers to capture market share early.
- Leveraging patent challenges and legal strategies to accelerate biosimilar product launches.
Risks:
- Stringent regulatory barriers in certain geographies.
- Delayed biosimilar approval or market entry.
- Competitive intensity leading to aggressive price erosion.
- Healthcare policy shifts favoring cost-effective alternatives over branded biologics.
Concluding Insights
The future landscape for NDC 59676-0562 (Rituximab) will be heavily shaped by biosimilar proliferation and evolving reimbursement models. While the current high-price environment reflects its market exclusivity, impending patent expirations herald significant price declines, fostering increased access but compressing margins for original manufacturers.
Stakeholders should prepare for a bifurcated market, with branded Rituximab maintaining premium status in select niche areas, while biosimilar versions gain predominant market share and drive substantial cost savings. Accurate strategic planning requires ongoing monitoring of patent statuses, biosimilar pipeline developments, and healthcare policy reforms.
Key Takeaways
- The Rituximab market is poised for substantial transformation, driven by biosimilar competition following patent expirations in key regions.
- Current prices for branded Rituximab range from $10,000 to $12,000 per 100 mg vial; biosimilars are approximately 40-60% cheaper.
- Price projections indicate a downward trend, with average biosimilar prices potentially settling around $3,000–$4,000 per vial by 2030.
- Manufacturers should strategically innovate, form collaborations, and adapt to shifting regulatory environments to retain competitiveness.
- Payers and policymakers will continue to influence market dynamics through reimbursement reforms and substitution policies that favor cost-effective biologics.
FAQs
1. When will biosimilars for Rituximab become dominant in the market?
Biosimilar adoption is expected to accelerate post-2025, following patent expirations. Their dominance could materialize within 3–5 years as market acceptance and regulatory approvals expand.
2. How do biosimilar prices compare to branded Rituximab currently?
Biosimilars are priced approximately 40-60% lower than branded versions, with initial costs around $4,000–$7,000 per 100 mg vial.
3. What factors influence Rituximab's future market price?
Patent expirations, biosimilar development, manufacturing innovations, regulatory policies, and healthcare reimbursement strategies are primary drivers.
4. Are there regional differences in Rituximab pricing?
Yes. The U.S. tends to have higher prices due to market structures and regulatory policies, while European and emerging markets may see lower prices and faster biosimilar adoption owing to different reimbursement frameworks.
5. How might new therapies impact Rituximab’s market share?
Emerging biologics and targeted therapies, including CAR-T cell treatments, could serve as competition, potentially reducing Rituximab's market share in certain indications.
References
- Grand View Research. "Biologics Market Size, Share & Trends Analysis Report." 2022.
- FDA. "Biosimilar Guidance and Patent Expirations," 2021.
- IQVIA, "Global Biosimilar Market Forecast," 2023.
- Healthcare Providers & Distributors. Average Wholesale Prices, 2023.
- Sandoz and Celltrion press releases, 2023.
Note: The above analysis is based on current market data, industry trends, and regulatory outlooks as of early 2023. Market conditions are subject to rapid change, and continuous monitoring is advised.
More… ↓
